International Association for the Study of Lung Cancer: Datopotamab Deruxtecan Does Not Meet Its Secondary Primary Endpoint in TROPION-Lung01, But Researchers Believe Therapy is Still Beneficial for Some Patients With Non-Squamous NSCLC
September 10, 2024
September 10, 2024
AURORA, Colorado, Sept. 10 (TNSres) -- The International Association for the Study of Lung Cancer issued the following news release on Sept. 9, 2024:
* * *
The data was presented today by Dr. Jacob Sands, Dana-Farber Cancer Institute in Boston, Mass., at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
* * *
(San Diego, Calif.-- September 9, 2024 10:57 a.m. PCT--Note: this abstract will be publish . . .
* * *
The data was presented today by Dr. Jacob Sands, Dana-Farber Cancer Institute in Boston, Mass., at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
* * *
(San Diego, Calif.-- September 9, 2024 10:57 a.m. PCT--Note: this abstract will be publish . . .